Kestra's Earnings Beat Masks Institutional Divide as FMR Buys, Citadel Sells

The headline numbers are clear. Kestra's second-quarter revenue of $22.6 million beat estimates by a solid $1.45 million, marking a 53% year-over-year increase. That's the growth story, and it's real. The company also raised its full-year revenue guidance to $91 million, a 52% jump from the prior year. Yet the bottom line tells a different story. Despite the top-line surge, KestraKMTS+9.76% posted a GAAP net loss of $32.8 million and a negative EPS of -$0.62. The real signal isn't in the revenue beat, but in whether the smart money sees a path through this loss to profitability.

The company's gross margin did improve to 50.6% from 39.6% a year ago, a key operational milestone. But that's not enough to offset the massive operating losses. The cash burn is significant, even with a balance sheet fortified by a $148 million net proceeds equity offering earlier in December. For now, the growth is being funded by capital, not profits.

So what are the insiders and institutional whales doing? The filings tell a mixed, but telling, story. Institutional activity in the third quarter of 2025 showed a net increase, with 55 institutional investors adding shares while 42 decreased positions. That's a net positive, but the moves of the largest players are more revealing. FMR LLC, the giant behind the Fidelity funds, made a massive addition of 1.58 million shares in Q3. That's skin in the game. On the flip side, Citadel Advisors and T. Rowe Price each made a complete exit, removing all their shares in that same quarter. This isn't a coordinated sell-off, but it highlights a split in conviction. The smart money is not monolithic.

The bottom line is that the revenue beat validates the growth thesis. But the persistent losses and the mixed institutional signals mean the market is waiting for proof of a sustainable business model. Until the GAAP losses narrow, the smart money will remain cautious. The real test is whether this growth translates into adjusted EBITDA profitability, not just top-line numbers.

The Smart Money Signal: Institutional Flows

The institutional filings for Q3 2025 paint a picture of a market divided. While the headline showed a net increase in ownership-with 55 institutional investors adding shares and 42 decreasing positions-the moves of the largest players tell a more nuanced story. This isn't a unified vote of confidence; it's a split in conviction.

On one side, you have a major buyer. FMR LLC, the powerhouse behind the Fidelity funds, made a decisive move, adding 1.58 million shares in the quarter. That's a 42.8% stake increase, a significant bet that signals strong alignment with the growth narrative. For the smart money, this kind of accumulation is skin in the game.

On the other side, two giants pulled out entirely. Citadel Advisors and T. Rowe Price Associates each completely exited their positions in Q3. That's a clean break, removing hundreds of thousands of shares each. Their exits suggest a loss of conviction, perhaps a view that the risks outweigh the growth potential at current valuations.

The bottom line is that the smart money isn't on the same page. The net institutional flow is positive, but it's driven by a few large buyers offsetting the complete sell-offs of others. This split signals high uncertainty. Professional investors are betting on the growth story, but they are hedging their bets with significant exits. Until we see more consistent accumulation from the largest funds, the institutional whale wallet remains a mixed signal.

The Insider Bet: CEO Skin in the Game

The CEO's words are bullish. Brian Webster has consistently highlighted sustained commercial momentum and raised guidance, framing the growth as a sign of execution. But the real test of alignment is what insiders do with their own money. For now, the record shows a clean slate.

There is no public record of CEO Webster selling company stock. That's not a negative signal-it's a lack of data. The absence of a sale, however, doesn't equate to a personal bet. The smart money looks for skin in the game, and the CEO's recent major financial move was strategic, not personal. In January, the company announced a $5 million equity investment in Biobeat Technologies as part of a collaboration. That's capital deployed for growth, but it's not an insider buying shares of Kestra itself.

The company's cash position provides a runway, but the burn rate is high. As of July 31, 2025, Kestra held $201.2 million in cash and cash equivalents. That's a war chest, but it's being consumed by massive operating losses. The Q1 FY26 GAAP net loss was $25.8 million, and the adjusted EBITDA loss was $19.4 million. The cash is funding the growth, not the profits.

The bottom line is that the CEO's personal financial alignment remains unclear. He's not selling, but he's not buying either. The strategic investment in Biobeat shows commitment to the company's future, but it's a corporate bet, not an insider's personal wager. Until we see insiders, particularly the CEO, using their own capital to buy shares at current prices, the signal of skin in the game is muted. The smart money waits for that personal bet before it fully aligns.

Catalysts and Risks: What to Watch

The growth thesis is on display, but the smart money is waiting for the cash to catch up. The near-term catalysts are clear: watch for the next institutional filings, monitor the Biobeat integration, and, most critically, see if the burn rate finally starts to ease.

The first major data point to watch is the next set of 13F filings. The split in conviction from Q3 2025-where FMR LLC bought heavily while Citadel and T. Rowe Price exited-shows how quickly sentiment can shift. The next quarter's filings will reveal if that divergence continues or if a new trend emerges. Are the whales doubling down on the growth story, or are they taking profits as losses persist? The pattern of accumulation or reduction from large funds like FMR will be a leading indicator of institutional confidence.

Then there's the Biobeat bet. The company's $5 million equity investment in Biobeat Technologies is a strategic move, but its payoff is not yet visible. The real test is whether this collaboration successfully enhances the ASSURE system's value proposition and accelerates adoption. Any update on the integration's progress or its impact on prescription growth will be a key signal. If the partnership fails to move the needle, it could undermine the narrative of a scalable, integrated platform.

The overriding risk, however, is the cash burn. Despite a $148 million net proceeds equity offering in December, the losses are widening. The Q1 FY26 adjusted EBITDA loss was $19.4 million, up from $15.7 million a year ago. The company's cash position has been reduced from $201.2 million in July to $175 million by October. The runway is stretching thin. The smart money's patience is finite. The real test is whether Kestra can translate its 50%+ revenue growth into adjusted EBITDA profitability before the war chest is depleted. Until that happens, the growth story remains a high-stakes bet on future cash flow.